ADIL shorts retreat as earnings beat lands ahead of next event

Adial Pharmaceuticals heads into its May 13 earnings event with short sellers in full retreat — and a surprise Q1 beat already in the market.

The most striking move this week is the collapse in short interest. Shorts fell nearly 70% over the past month, dropping from roughly 115,000 shares in early April to just under 36,000 shares by May 7. That takes short interest as a percentage of the free float down to approximately 0.15% — a level so low it carries virtually no directional signal from the short side. The unwind accelerated into the Q1 print, with a single-session drop of 34% on May 7 alone.

The borrow market tells the same story. Cost to borrow has eased steadily from a near-term peak around 2.47% in mid-April to 1.48% now, the lowest of the past six weeks. Availability has loosened alongside it, with the lending pool now 55% utilised — well off the 94% peak recorded at the 52-week high. At that prior tightness, borrow was a real constraint. At current levels, there is no meaningful squeeze pressure.

The catalyst driving those moves is now public. Q1 EPS came in at -$1.48 against an estimate of -$2.73 — a $1.25 beat that scored a maximum importance rating in the ORTEX news feed. Adial is a pre-revenue clinical-stage company developing treatments for alcohol use disorder (AUD). Losses narrowing by this magnitude in a single quarter shifted the near-term narrative quickly. The stock pulled back 7.7% on the week to $1.43 despite gaining 0.7% on the day the result landed, suggesting investors locked in gains from an earlier run into the print.

The most recent earnings history reinforces the pattern of post-event weakness. Each of the three prior results produced a negative one-day move: -1.6%, -8.0%, and -4.9%. Five-day moves were worse, averaging a loss of roughly 6%. The next confirmed event is scheduled for May 13. Whether Thursday's readout carries additional clinical or financial disclosure beyond what has already surfaced in the 10-Q filing from May 8 will determine whether that pattern holds.

The analyst picture is thin and dated. One buy-rated analyst carries a $25 mean price target as of late April — against a stock trading at $1.43. That gap is too wide to reconcile without either a reverse split or a stale legacy target; treat it with caution rather than as a current signal. Institutional ownership is sparse: Armistice Capital holds roughly 7.8% of shares outstanding as the dominant external holder, with the next tier — Citadel, Vanguard, Geode — each holding well under 1%.

The setup heading into May 13 is one of thin short positioning, a loosening borrow market, and a company that already delivered an earnings beat this week. What to watch is whether the confirmed May 13 event brings incremental clinical data on the AD04 programme — that, not the financial line items, is the catalyst that has historically moved the stock.